Abstract Number: 1499 • 2019 ACR/ARP Annual Meeting
Golimumab Persistence in Biologic Naive and Non-Naive Patients with Axial Spondyloarthritis: Results of the GO PRACTICE Study
Background/Purpose: The pivotal GO AFTER study [1] and the ongoing observational GO BEYOND study investigate GLM efficacy in rheumatoid arthritis (RA) patients who previously received…Abstract Number: 1511 • 2019 ACR/ARP Annual Meeting
Drug Survival of Ustekinumab in Psoriatic Arthritis: A Real-World Multicentric Cohort of 252 Patients
Background/Purpose: Ustekinumab (UST) is a new biological Disease-modifying AntiRheumatic Drug (bDMARD) available in psoriatic arthritis (PsA), targeting respectively IL12-23. Real-world data are missing for this…Abstract Number: 1529 • 2019 ACR/ARP Annual Meeting
The Efficacy and Safety of Anti-TNFα Treatment in Ankylosing Spondylitis Patients with Late Onset Compared to Those with Adult Onset; The Data from TURKBIO Registry
Background/Purpose: The first symptoms of ankylosing spondylitis (AS) patients usually begin prior to 45 years, but can occur later in life. The purpose of this…Abstract Number: 1901 • 2019 ACR/ARP Annual Meeting
Serious Infections in Offspring Exposed in Utero to Non-TNFi Biologics and Tofacitinib
Background/Purpose: During pregnancy, maternal circulating immunoglobulins G (IgG) are actively transported across the placenta through their Fc portion. Thus, TNFi and other biologics harbouring an Fc…Abstract Number: 2111 • 2019 ACR/ARP Annual Meeting
Symptomatic Coccidioidomycosis Infections in Patients on Biologic Therapies
Background/Purpose: Studies have shown an increased risk of coccidioidomycosis infection in immunosuppressed patients. However, relationship of coccidioidomycosis infections with different immunosuppressive medication is not well…Abstract Number: 593 • 2018 ACR/ARHP Annual Meeting
Predictors of Persistence of Biologic Drug Step-Down Strategies in Inflammatory Arthritis: An Observational Study in Clinical Practice up to Seven Years of Follow-up
Background/Purpose: Recommendations and guidelines for the management of Rheumatoid Arthritis (RA) and spondyloarthritis (SpA) with bDMARD include dose-tapering as an adequate option for patients on…Abstract Number: 1940 • 2018 ACR/ARHP Annual Meeting
Reductions in Absolute Neutrophil Count (ANC) with Sarilumab Resulting in Dose Delays or Dose Decreases: Effects on Efficacy and Safety
Background/Purpose: In sarilumab randomized controlled trials (RCTs), dose delay and/or reduction was recommended for management of patients who developed neutropenia Grade (G) 3 (ANC ≥500…Abstract Number: 2858 • 2018 ACR/ARHP Annual Meeting
Gaps in Patient Safety Performance before Treatment with Biologic Disease-Modifying Antirheumatic Drugs or Tofacitinib in a Large Academic Healthcare System
Background/Purpose: Treatment with biologic disease-modifying antirheumatic drugs (DMARDs) and tofacitinib confer increased risk of life-threatening infections, including reactivation of latent tuberculosis infection (LTBI), hepatitis B…Abstract Number: 626 • 2018 ACR/ARHP Annual Meeting
The Comparative Effectiveness of Cycling Tumor Necrosis Factor Inhibitor (TNFi) Versus Swapping to a Nontnfi on Patient-Reported Functional Ability of Patients with Rheumatoid Arthritis
Background/Purpose: Data on patient-reported functional ability to evaluate the optimal strategy for patients who have failed to first TNFi is scarce. Patient-reported outcomes are a…Abstract Number: 2044 • 2018 ACR/ARHP Annual Meeting
Impaired microRNA Processing in Neutrophils from Rheumatoid Arthritis Patients Confers Their Pathogenic Profile. Modulation By Biological Therapies
Background/Purpose: Neutrophils are the most abundant cells in synovial fluid, having all the features of activated cells in rheumatoid arthritis (RA), including prolonged cell survival,…Abstract Number: 2877 • 2018 ACR/ARHP Annual Meeting
The Comparative Effectiveness of First-Line Tumor Necrosis Factor Inhibitor (TNFi) Compared with Non-TNFi Agents in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
Background/Purpose: RA patients who are intolerant or have an inadequate response to conventional synthetic DMARDs (csDMARDs) can be treated with a biologic DMARD (bDMARD). Tumor…Abstract Number: 627 • 2018 ACR/ARHP Annual Meeting
Corticosteroid Utilization before and after Initiation of Biologic Dmards between Patients with Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory, systemic autoimmune disease that causes several health problems, such as pain, joint destruction and loss of function.…Abstract Number: 2078 • 2018 ACR/ARHP Annual Meeting
Induction of Netosis in Ankylosing Spondylitis: Association to Disease Pathogenesis and Modulation By Anti-Tnfα Therapy
Background/Purpose: NETosis has been suggested to play a central role in several rheumatology diseases. Nevertheless, this process, and its modulation in therapeutic response has not…Abstract Number: 692 • 2018 ACR/ARHP Annual Meeting
TNF Inhibitor Dose Tapering in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis
Background/Purpose: Patients with axial spondyloarthritis (axSpA) who have achieved a stable disease state and are undergoing treatment with tumour necrosis factor inhibitor (TNFi) therapy may…Abstract Number: 2190 • 2018 ACR/ARHP Annual Meeting
Means of Collaboration between Ophthalmologists, Rheumatologists and Internists in the Management of Non-Infectious Uveitis: A Nationwide Study
Background/Purpose: When uveitis is believed to be part of an underlying systemic disease or when a systemic treatment is required, a multi-disciplinary approach is usually…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 14
- Next Page »